Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Genetic predisposition to bleeding during oral anticoagulants treatment].

Anales del sistema sanitario de Navarra - 1 Jan 2000

Montes Díaz R, Nantes O, Molina E, Zozaya J, Hermida J

Abstract excerpt

The degree of anticoagulation obtained during oral anticoagulation therapy with vitamin K antagonists (VKA) varies among patients due to individual and environmental factors. The rate of anticoagulation influences the hemorrhagic risk. Therefore, it is plausible that patients specially sensitive to oral anticoagulants are at higher hemorrhagic risk, specially during the first weeks. The role of a series of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hemorrhage

Share to Mixed Function Oxygenases

Share to Polymorphism, Genetic

Share to Vitamin K

Source

Identifiers

PMID: 19165291

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Genetic predisposition to bleeding during oral anticoagulants treatment].PMID 19165291Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Genetic susceptibility to hemorrhagic complications during warfarin therapy.Semantic proximity Read ↗

VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Semantic proximity Read ↗

Investigating warfarin variability : the contribution of clinical, genetic, and environmental factorsSemantic proximity Read ↗

[Effect of genetic variations on adjusting of warfarin dose].Semantic proximity Read ↗

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].Semantic proximity Read ↗

[Genetic determinants of response to vitamin K antagonists].Semantic proximity Read ↗

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.